23 feb 2012 anni - Ado-Trastuzumab Emtansine (T-DM1) Approved
Descrizione:
FDA approves Ado-Trastuzumab Emtansine (T-DM1) for the treatment of patients with metastatic HER2-positive breast cancer. HER2 makes up 20% of all cases for breast cancer.
Aggiunto al nastro di tempo:
Data: